Amendment: SEC Form SC 13G/A filed by CryoPort Inc.
$CYRX
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/7/2024 | $20.00 → $8.00 | Buy → Hold | Jefferies |
| 7/31/2024 | $19.00 → $15.00 | Neutral → Buy | B. Riley Securities |
| 5/3/2024 | $22.00 → $19.00 | Buy → Neutral | B. Riley Securities |
| 4/4/2024 | $17.00 → $21.00 | Buy | Jefferies |
| 3/13/2024 | $19.00 → $18.00 | Buy | Needham |
| 8/17/2023 | $16.00 | Equal-Weight | Morgan Stanley |
| 8/10/2023 | $15.00 | Overweight → Equal-Weight | Stephens |
| 7/18/2023 | $28.00 → $17.00 | Buy → Neutral | UBS |
Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of 691 global clinical trials as of September 30, 2024Company reaffirmed full year 2024 revenue guidance of $225 to $235 millionNASHVILLE, Tenn., Nov. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences industry, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2024. Jerrell Shelton, CEO of Cryoport, remarked, "O
NASHVILLE, Tenn., Oct. 29, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2024 on Thursday, November 7, 2024 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Third Quarter 2024 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Thu
Revenue improved sequentially across all businessesCommercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially A record total of 684 global clinical trials supported as of June 30, 2024Cost reduction initiatives anticipated to result in approximately $22 million of annualized cost savings and drive Cryoport towards its goal of profitable growth, as well as a return to positive Adjusted EBITDA in 2025Company provides updated 2024 full-year revenue guidance of $225 to $235 millionNASHVILLE, Tenn., Aug. 6, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences, today announced financial results f
NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a member of the Board, effective March 15, 2021. Linda Baddour is a senior executive with over twenty years of experience in healthcare, life sciences and pharmaceuticals. "Our corporate governance underpins all that we do at Cryoport and we are delighted to strengthen our Board as we leverage our newly expanded global footprint and advanced temperature-controlled supply chain platform to spur our growth," said Jerrell She
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously served as a member of BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries with 40 years of business experience. He currently serves as Co-Founder and CEO of ClearIt, L
Facility Dedicated to Cryopreservation of Leukapheresis Starting Materials to Support Clinical and Commercial Cell-Based Therapy Programs NASHVILLE, Tenn., Nov. 12, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced the opening of its newest IntegriCell™ facility in Villers-le-Bouillet, Liege, Belgium. The Center of Excellence is now fully operational and prepared to support the development and commercialization of cell-based therapies with advanced cryopreservation solutions for leukapheresis, a common starting material.
Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of 691 global clinical trials as of September 30, 2024Company reaffirmed full year 2024 revenue guidance of $225 to $235 millionNASHVILLE, Tenn., Nov. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences industry, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2024. Jerrell Shelton, CEO of Cryoport, remarked, "O
NASHVILLE, Tenn., Oct. 29, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2024 on Thursday, November 7, 2024 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Third Quarter 2024 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Thu
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
Jefferies downgraded Cryoport from Buy to Hold and set a new price target of $8.00 from $20.00 previously
B. Riley Securities upgraded Cryoport from Neutral to Buy and set a new price target of $15.00 from $19.00 previously
B. Riley Securities downgraded Cryoport from Buy to Neutral and set a new price target of $19.00 from $22.00 previously
SC 13G - Cryoport, Inc. (0001124524) (Subject)
SC 13G/A - Cryoport, Inc. (0001124524) (Subject)
SC 13G/A - Cryoport, Inc. (0001124524) (Subject)
10-Q - Cryoport, Inc. (0001124524) (Filer)
8-K - Cryoport, Inc. (0001124524) (Filer)
10-Q - Cryoport, Inc. (0001124524) (Filer)
Shares of Helen of Troy Limited (NASDAQ:HELE) fell sharply during Tuesday's session after the company reported soft first-quarter earnings and lowered its FY25 guidance. Helen of Troy reported quarterly earnings of 99 cents per share which missed the analyst consensus estimate of $1.59. The company reported quarterly sales of $416.85 million which missed the analyst consensus estimate of $446.22 million, according to data from Benzinga Pro. Helen of Troy shares dipped 30.3% to $62.06 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Soligenix, Inc. (NASDAQ:SNGX) shares jumped 195% to $5.90 after the company announced interim results for extende
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday. Shares of ResMed Inc. (NYSE:RMD) fell sharply during Monday's session following sleep apnea data from Lilly. Citigroup analyst Mathieu Chevrier downgraded ResMed from Buy to Neutral. ResMed shares dipped 10.4% to $184.35 on Monday. Here are some other big stocks recording gains in today’s session. Molecular Partners AG (NASDAQ:MOLN) shares dipped 22.6% to $7.43. Cryoport, Inc. (NASDAQ:CYRX) fell 19.9% to $7.77. Cryoport announced a strategic partnership with Minaris Regenerative Medicine for cell and gene therapies advancement. BridgeBio Pharma, Inc. (NASDAQ:BBIO) dipped 19.2% to $22.1
Partnership Will Provide Cell and Gene Therapy Industry with Fully Integrated Logistics and Manufacturing Services for Regenerative Medicine Products